ALLO נכסי החברה Allogene Therapeutics Inc

This price chart from GURU.Markets illustrates the price action of Allogene Therapeutics (ALLO) assets, which currently reach 510.30. Allogene Therapeutics brings together leading immunologists attracted by a robust scientific foundation and investments in cancer therapy. Meanwhile, the business relies on growing clinical interest in immediate patient treatment, although international trade conflicts and logistical risks in Asia complicate global supplies.

For Allogene Therapeutics (ALLO), the gross assets figure reflects the dynamics of the resource base amid intensive R&D funding in the absence of revenue. This metric determines the total value of assets and liabilities, serving as an indicator of business resilience against cash flow gaps. The value is calculated inversely via return on assets (ROA), allowing for an assessment of the actual efficiency of capital utilization. A downward trend signals base degradation and the risk of reserve depletion.